Melanoma is remarkably heterogenous. The different subtypes vary in their immunological and clinical profiles, and these differences can have implications for the most appropriate treatment approaches in both advanced disease and adjuvant settings. In this podcast, medical oncologist at Chris O’Brien Lifehouse Jenny Lee talks to Associate Professor Matteo Carlino, a consultant medical oncologist at ...
Treatment selection in histological subtypes of melanoma
15 Feb 2021
Sponsored by Bristol Myers Squibb Australia Pty Ltd